Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Br J Cancer ; 124(12): 1921-1933, 2021 06.
Article in English | MEDLINE | ID: mdl-33785878

ABSTRACT

BACKGROUND: Dynamic transitions of tumour cells along the epithelial-mesenchymal axis are important in tumorigenesis, metastasis and therapy resistance. METHODS: In this study, we have used cell lines, 3D spheroids and tumour samples in a variety of cell biological and transcriptome analyses to highlight the cellular and molecular dynamics of OSCC response to ionising radiation. RESULTS: Our study demonstrates a prominent hybrid epithelial-mesenchymal state in oral squamous cell carcinoma cells and tumour samples. We have further identified a key role for levels of E-cadherin in stratifying the hybrid cells to compartments with varying levels of radiation response and radiation-induced epithelial-mesenchymal transition. The response to radiation further entailed the generation of a new cell population with low expression levels of E-cadherin, and positive for Vimentin (ECADLow/Neg-VIMPos), a phenotypic signature that showed an enhanced capacity for radiation resistance and invasion. At the molecular level, transcriptome analysis of spheroids in response to radiation showed an initial burst of misregulation within the first 30 min that further declined, although still highlighting key alterations in gene signatures. Among others, pathway analysis showed an over-representation for the Wnt signalling pathway that was further confirmed to be functionally involved in the generation of ECADLow/Neg-VIMPos population, acting upstream of radiation resistance and tumour cell invasion. CONCLUSION: This study highlights the functional significance and complexity of tumour cell remodelling in response to ionising radiation with links to resistance and invasive capacity. An area of less focus in conventional radiotherapy, with the potential to improve treatment outcomes and relapse-free survival.


Subject(s)
Carcinoma, Squamous Cell/pathology , Epithelial-Mesenchymal Transition , Mouth Neoplasms/pathology , Radiation Tolerance/genetics , Carcinoma, Squamous Cell/genetics , Cell Line, Tumor , Cell Movement/genetics , Epithelial-Mesenchymal Transition/genetics , Epithelial-Mesenchymal Transition/radiation effects , Gene Expression Profiling , Gene Expression Regulation, Neoplastic/radiation effects , Genes, Switch/physiology , Genes, Switch/radiation effects , Genetic Association Studies , Humans , Mouth Neoplasms/genetics , Neoplasm Invasiveness , Phenotype , Radiation, Ionizing , Transcriptome/radiation effects , Wnt Signaling Pathway/genetics , Wnt Signaling Pathway/radiation effects
2.
PLoS One ; 9(2): e87840, 2014.
Article in English | MEDLINE | ID: mdl-24505322

ABSTRACT

The ß2-adrenergic receptor agonist, albuterol, has been reported beneficial in treating several forms of congenital myasthenia. Here, for the first time, we examined the potential benefit of albuterol in a mouse model of anti-Muscle Specific Kinase (MuSK) myasthenia gravis. Mice received 15 daily injections of IgG from anti-MuSK positive patients, which resulted in whole-body weakness. At neuromuscular junctions in the tibialis anterior and diaphragm muscles the autoantibodies caused loss of postsynaptic acetylcholine receptors, and reduced the amplitudes of the endplate potential and spontaneous miniature endplate potential in the diaphragm muscle. Treatment with albuterol (8 mg/kg/day) during the two-week anti-MuSK injection series reduced the degree of weakness and weight loss, compared to vehicle-treated mice. However, the compound muscle action potential recorded from the gastrocnemius muscle displayed a decremental response in anti-MuSK-injected mice whether treated with albuterol or vehicle. Ongoing albuterol treatment did not increase endplate potential amplitudes compared to vehicle-treated mice nor did it prevent the loss of acetylcholine receptors from motor endplates. On the other hand, albuterol treatment significantly reduced the degree of fragmentation of endplate acetylcholine receptor clusters and increased the extent to which the remaining receptor clusters were covered by synaptophysin-stained nerve terminals. The results provide the first evidence that short-term albuterol treatment can ameliorate weakness in a robust mouse model of anti-MuSK myasthenia gravis. The results also demonstrate that it is possible for albuterol treatment to reduce whole-body weakness without necessarily reversing myasthenic impairment to the structure and function of the neuromuscular junction.


Subject(s)
Adrenergic beta-2 Receptor Agonists/pharmacology , Albuterol/pharmacology , Autoantibodies/toxicity , Myasthenia Gravis, Autoimmune, Experimental/drug therapy , Animals , Autoantibodies/immunology , Female , Humans , Mice , Muscle, Skeletal/immunology , Muscle, Skeletal/pathology , Myasthenia Gravis, Autoimmune, Experimental/chemically induced , Myasthenia Gravis, Autoimmune, Experimental/immunology , Myasthenia Gravis, Autoimmune, Experimental/pathology , Neuromuscular Junction/immunology , Neuromuscular Junction/pathology , Receptor Protein-Tyrosine Kinases/immunology
3.
J Vis Exp ; (94)2014 Dec 26.
Article in English | MEDLINE | ID: mdl-25590231

ABSTRACT

The neuromuscular junction (NMJ) is the large, cholinergic relay synapse through which mammalian motor neurons control voluntary muscle contraction. Structural changes at the NMJ can result in neurotransmission failure, resulting in weakness, atrophy and even death of the muscle fiber. Many studies have investigated how genetic modifications or disease can alter the structure of the mouse NMJ. Unfortunately, it can be difficult to directly compare findings from these studies because they often employed different parameters and analytical methods. Three protocols are described here. The first uses maximum intensity projection confocal images to measure the area of acetylcholine receptor (AChR)-rich postsynaptic membrane domains at the endplate and the area of synaptic vesicle staining in the overlying presynaptic nerve terminal. The second protocol compares the relative intensities of immunostaining for synaptic proteins in the postsynaptic membrane. The third protocol uses Fluorescence Resonance Energy Transfer (FRET) to detect changes in the packing of postsynaptic AChRs at the endplate. The protocols have been developed and refined over a series of studies. Factors that influence the quality and consistency of results are discussed and normative data are provided for NMJs in healthy young adult mice.


Subject(s)
Microscopy, Confocal/methods , Nerve Tissue Proteins/metabolism , Neuromuscular Junction/physiology , Synapses/physiology , Animals , Female , Fluorescence Resonance Energy Transfer , Mice , Mice, Inbred C57BL , Motor Endplate/metabolism , Neuromuscular Junction/anatomy & histology , Neuromuscular Junction/metabolism , Receptors, Cholinergic/metabolism , Synapses/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL